XYXiaomin Yu

Xiaomin Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaomin Yu has a total of 269 co-authors. Here are the top co-authors by number of shared publications:

  • Qing Zhou

    Liangzhu Laboratory of Zhejiang University, and Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    24 shared publications
  • Xu Han

    Liangzhu Laboratory, Zhejiang University

    15 shared publications
  • Jiahui Zhang

    National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    11 shared publications
  • Jun Wang

    Liangzhu Laboratory of Zhejiang University, Department of Rheumatology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China

    10 shared publications
  • Xiangwei Sun

    Liangzhu Laboratory, Zhejiang University, Hangzhou, Zhejiang 311121, China

    10 shared publications
  • Chenlu Liu

    Life Sciences Institute Zhejiang University Hangzhou China

    9 shared publications

Latest Publications

  • Open Access

    Deficiency of NBAS causes immune dysregulation due to hyperactivation of IFN signaling

    by Chenlu Liu, Liang Zhang, Meiping Lu, Yunyan Shen, Yuhao Yao, Fei Liu, Qintao Wang, Benshan Zhang, Li Guo, Xiaozhong Li, et al.

    NBAS deficiency is a multisystem disorder, but its immunologic manifestations and underlying mechanisms remain poorly defined. Here, we expand the genotypic and phenotypic spectrum of NBAS deficiency through four patients carrying five loss-of-function NBAS mutations. Minigene assays and RNA analysis showed that these splicing or missense mutations resulted in aberrant alternative splicing. Clinically, the patients showed early-onset recurrent or persistent cytopenias and immune dysregulation, together with severe infections, inflammatory activation, and multi-organ involvement, including renal and neurologic manifestations. Transcriptomic analysis revealed overactivation of type I interferon signaling pathways compared with healthy controls, and single-cell RNA sequencing demonstrated that this upregulated inflammation was predominantly driven by myeloid cells. Together, these findings identify NBAS deficiency as a cause of immune dysregulation characterized by myeloid-driven type I interferonopathy, expand the clinical spectrum of NBAS-related disorders, and highlight the critical role of NBAS in maintaining immune homeostasis.

  • Open Access

    Correction: Genetically defined systemic autoinflammatory diseases in pediatric patients with Behçet’s disease

    by Shaoling Zheng, Pui Y Lee, Qing Zhou, Xu Han, Xuechan Huang, Yukai Huang, Jiajun Chen, Chun Zheng, Xiaolin Fang, Jianhua Yu, et al.

  • Open Access

    Cytotoxic lymphocyte death drives monocyte activation and TNF/IFN-γ synergism in TBK1 deficiency

    by Xu Han, Jialin Dai, Jihong Xiao, Yanqiu Tian, Guannan Jiang, Taijie Jin, Wenjie Zheng, Huaxiang Wu, Wei Dong, Huanming Yang, et al.

    TBK1 deficiency drives the pathogenesis of inborn errors of cell death (IECDs). However, the underlying cellular mechanisms remain unclear. Here, we identified a novel homozygous loss-of-function TBK1 variant resulting in exon 18 deletion (p.R621Sfs*21) that led to loss of TBK1 expression in a patient with systemic juvenile idiopathic arthritis (sJIA). The patient’s myeloid cells exhibited predominantly upregulated inflammatory responses, including TNF, NF-κB, and IFN (interferon)-γ signaling, while type I IFN responses were partially impaired in responses to agonists of pattern recognition receptors (PRRs). Analysis of the patient’s peripheral blood mononuclear cells (PBMCs) and healthy donor-derived TBK1 -knockout T cells showed that TBK1 -deficient cytotoxic lymphocytes are more susceptible to RIPK1-dependent cell death. Cell-cell communication analysis and combined treatment targeting TNF and IFN-γ highlighted a driving role of TNF/IFN-γ synergism in inflammatory activation of monocytes/T cells in the patient’s PBMCs, which was triggered by uncontrolled programmed cell death resulting from TBK1 deficiency. Long-term follow-up demonstrated that combined TNF and JAK inhibitor therapy was effective in suppressing the patient’s inflammatory responses. Our results identified a novel pathogenic TBK1 variant and demonstrated that cytotoxic lymphocytes are the primary drivers of aberrant cell death through a T cell-myeloid axis dependent on TNF/IFN-γ synergism. These results support combined TNF and JAK inhibition as an effective therapeutic strategy for TBK1 deficiency.

  • Open Access

    Genetically defined systemic autoinflammatory diseases in pediatric patients with Behçet’s disease

    by Shaoling Zheng, Pui Y Lee, Qing Zhou, Xu Han, Xuechan Huang, Yukai Huang, Jiajun Chen, Chun Zheng, Xiaolin Fang, Jianhua Yu, et al.

    Objectives: The aim of this study was to characterize the genetic basis of Behçet’s disease (BD) and mimics in a pediatric cohort. Methods: We retrospectively studied 34 patients of pediatric BD and mimics who underwent whole-exome sequencing (WES) in our center from 2020 to 2025. Clinical characteristics and laboratory parameters of the patients with or without genetically defined systemic autoinflammatory diseases (SAIDs) were compared. Results: WES identified 10 probands with genetically defined SAID (the SAID+ group). Nine probands possessed pathogenic or likely pathogenic germline variants in RELA , TNFAIP3 (encoding A20), or GATA2 . One proband was found to have trisomy 8. Five of the SAID+ probands exhibited parentally inherited variants, while the remaining four probands possessed de novo variants. Compared to pediatric BD patients without genetically determined SAID (the ped-BD group, n = 24), the SAID+ group exhibited earlier disease onset and greater prevalence of recurrent fever episodes, intestinal involvement, and hematologic abnormalities. Laboratory studies revealed higher levels of inflammatory markers and serum cytokines including IL-1β, IL-2, IL-10, and TNFα in the SAID+ group. Corticosteroid treatment was commonly utilized in all patients, while the use of biologic DMARDs was more common in the SAID+ group. Conclusion: Pediatric patients with autoinflammatory diseases mimicking BD have heightened systemic inflammation and more severe organ involvement that necessitate intensified immunosuppressive regimens. Genetic evaluation should be considered for BD cases with early disease onset, recurrent fever, enteritis, intestinal ulcers, or hematologic abnormalities.

  • A Multi‐Center Integrative Cohort Characterizing the Genetic, Clinical, and Transcriptomic Features of ACP5 Deficiency

    by Shiling Zhong, Shuangyue Ma, Yasmine El Chazli, Jika Zheng, Xiangwei Sun, Sarah S. Allam, Jun Wang, Xu Han, Chenlu Liu, Lin Liu, et al.

    Objectives: Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is a rare disorder caused by biallelic mutations in ACP5. This study systematically evaluates genetic landscape, clinical features, treatment, and transcriptomics in SPENCDI. Methods: Whole‐exome sequencing was performed for genetic diagnosis of patients from multiple centers, and tartrate‐resistant acid phosphatase (TRAP) activity was measured for novel variants. Previously reported cases were integrated with the current cohort for analysis of genotypes, clinical characteristics, laboratory findings, and treatment responses. Bulk and single‐cell RNA sequencing investigated immune signaling alterations. Results: We identified 17 patients with ACP5 deficiency from Egypt and China, discovering five novel pathogenic variants (A260D, L257P, G32D, K190Nfs*22, and T305Nfs*12). Three novel missense variants were detected with loss of TRAP activity. Clinical manifestations involve multiple systems, with the skeletal system most frequently involved (32.31%), where skeletal dysplasia (94.32%) and short stature (81.82%) are the predominant features. Patients showed elevated inflammatory activity, with enrichment of the NF‐κB, MAPK, and cell death pathways, as well as upregulation of type I interferon genes in monocytes. Enhanced IFN‐γ signaling interactions between monocytes and Natural Killer cells were observed. Therapeutically, Prednisolone and Azathioprine were the most common effective drugs, while patients treated with the Janus kinase inhibitors Ruxolitinib or Upadacitinib achieved a partial response. Conclusions: This study expanded the genetic and clinical spectrum of ACP5 deficiency. An upregulated interferon signature was revealed, and monocytes were identified as a major cellular source of inflammation. These results provide valuable insights for improving the diagnosis and treatment of SPENCDI.

  • Reply

    by Jinjian Fu, Xiaomin Yu, Jun Wang, Qing Zhou, Qiong Fu

  • Open Access

    IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses

    by Yudie Fei, Lin Liu, Shuangyue Ma, Ying Jin, Shihao Wang, Liang Zhang, Jun Yang, Yi Liu, Meiping Lu, Jing Xue, et al.

    Interleukin-1 receptor-associated kinase 2 (IRAK2) is essential for the Myddosome complex formation downstream of Toll-like receptors. We identify twelve patients with a homozygous loss-of-function copy number variant in IRAK2, designated IRAK2-∆ex2. Most patients present with recurrent infections, autoantibody production, and gastrointestinal ulceration. Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases. The IRAK2-∆ex2 protein fails to interact with IRAK4, leading to impaired activation of nuclear factor kappa B signaling via the Myddosome complex. An elevated type I interferon signature is observed in the patients, which is confirmed in bone marrow-derived macrophages from knock-in mice and knockout cell lines. Mechanistically, our data are consistent with engagement of a TRIF-dependent interferon pathway. Baricitinib attenuates the elevated interferon signature in patient-derived cells ex vivo and cell lines. Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.


  • Open Access

    TLR1 deficiency associates with immune dysregulation and colitis

    by Yusha Wang, Xu Han, Libo Wang, Jinbo Wang, Qintao Wang, Wen Xiong, Jun Yang, Li Guo, Lingli Qi, Wei Dong, et al.

    Toll-like receptor 1 (TLR1), a member of the TLR family, assumes a pivotal role in pathogen recognition and the activation of innate immunity. In this study, we have identified a homozygous truncating TLR1 variant associated with immune dysregulation and colitis. Peripheral blood mononuclear cells derived from the patient manifested robust inflammatory signatures and defective TLR1 signaling responses. TLR1-deficient cells demonstrated impaired production of a wide-spectrum of inflammatory cytokines, antimicrobial peptides, and the anti-inflammatory cytokine IL-10 following stimulation with TLR1 ligand. This defect culminated in impaired bactericidal activity and dysregulated termination of the inflammatory response, especially characterized by a significant enhancement of the CXCR3 signaling pathway. TLR1-KO mice exhibited increased susceptibility to Salmonella Typhimurium infection and dextran sulfate sodium-induced colitis, with augmented infiltration of monocytes and macrophages in the pathological colon. The administration of IL-10 significantly alleviated the colitis phenotype associated with TLR1 deficiency in mice. This investigation underscores the crucial function of TLR1 in orchestrating a context-appropriate immune response to microbial invasion while averting excessive inflammation, thereby highlighting its indispensable role in human physiology and disease.

  • Deficiency of AP1M2 Causes a New Autoinflammatory Disease With Colitis

    by Taijie Jin, Jialin Dai, Chenlu Liu, Renkui Bai, Rachel Eisenberg, Yusha Wang, Jiahui Zhang, Wei Yin, Katrina Allis, Lindsay B. Henderson, et al.

    Objective: This study was the first to identify the biallelic loss‐of‐function variant in AP1M2 as the cause of autoinflammatory disease with colitis and aimed to elucidate the pathogenesis of AP1M2 deficiency in mice and humans. Methods: We collected a blood sample and serum sample from a patient for genetic diagnosis and determination of inflammatory cytokines, respectively. Ap1m2 ‐deficient mice on the C57BL/6 background and DLD‐1 cells were used to dissect the functional role of Ap1m2 in serum and intestines. Stereo‐seq was performed on Ap1m2 −/− and Ap1m2 −/− :: Tnfr1 −/− mouse samples to investigate the regulatory role of Tnfr1 signaling in the pathogenesis of Ap1m2 deficiency–caused intestinal inflammation. Superrevolution imaging and clathrin‐coated vesicle enrichment were used to explore the molecular mechanism by which AP1M2 suppresses NF‐κB activation and chemokine production. Results: Ap1m2 −/− mice exhibited elevated chemokine production in serum and spontaneously developed intestinal inflammation, which phenocopies the patient with the AP1M2 variant. Mechanistically, the deficiency of intestinal epithelial specific AP1M2 expression resulted in accumulation of TNFR1‐signaling downstream proteins, including RIPK1, TBK1, IKKα/β, and NEMO, leading to enhanced NF‐κB activation and subsequent chemokine overproduction. Tnfr1 knockout rescued gastrointestinal inflammation induced by Ap1m2 deficiency through suppressing NF‐κB activation and chemokine production. Conclusion: This study identifies the deficiency of AP1M2 as the cause of a new autoinflammatory disease with colitis and highlights the critical function of AP‐1 in suppressing NF‐κB activation and chemokine production. image